T. Petit

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
T Petit, T. Petit, Thierry Petit
Publication record
216 papers · 5,965 citations · H-index 40

PAPERS

Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
202323 citationsauthor #16
Baseline quality of life and chemotherapy toxicities in patients with early breast cancer
20236 citationsauthor #14
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials
20230 citationsauthor #13
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
202312 citationsauthor #18
Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer.
20232 citationsauthor #7
Training and validation of a model predicting clusters of long-term cancer-related behavioral symptoms (CRBS) after breast cancer (BC).
20230 citationsauthor #5
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study
202311 citationsauthor #11
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.
202223 citationsauthor #18
Treatment patterns and their impact on the outcome of patients with HR+/HER2+ metastatic breast cancer in a large real-world cohort.
20220 citationsauthor #4
Abstract OT2-03-01: RNA disruption assay (RDA) - Breast cancer response evaluation for individualized therapy (brevity/brevity-02)
20220 citationsauthor #4
2022-RA-1551-ESGO Impact of age on first line treatments of ovarian cancer and their outcomes: results from the Unicancer ESME OVR real-world database
20221 citationsauthor #15
Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial
202220 citationsauthor #13
Abstract P1-17-07: Consequences of stopping a 4/6 cyclin D-dependent kinase Inhibitor in metastatic breast cancer patients with clinical benefit on endocrine treatment, in the context of the COVID-19 outbreak
20220 citationsauthor #10
Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer
20223 citationsauthor #19
Abstract OT2-15-01: Updated analysis of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in patients (pts) with HER2 positive/amplified (HER2+) metastatic breast cancer (MBC) who progressed on previous anti-HER2 ADCs
20223 citationsauthor #2
The Impact of an Incidental Dose on Axillary Tumor Control and Toxicity in Localized Breast Cancer: A Retrospective Analysis
20224 citationsauthor #6
Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
20223 citationsauthor #4
Abstract P2-13-26: Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer (BC): First real-life data from the cohort temporary authorization for use (cATU) program in France
20220 citationsauthor #1
Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)
202281 citationsauthor #16
Abstract P4-05-02: Impact of hormone receptor status on clinicopathological characteristics and outcomes among HER2-positive metastatic breast cancer patients in the ESME database
20220 citationsauthor #4
Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
20225 citationsauthor #24
Abstract P1-18-19: Long term results with everolimus in advanced hormone receptor positive breast cancer in a multicenter national real world observational study (ESME)
20220 citationsauthor #11
Abstract P1-18-16: First line aromatase inhibitor (AI) + palbociclib with randomized switch to fulvestrant + palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Global safety results of PADA-1, a UCBG-GINECO phase III trial
20220 citationsauthor #13
Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study
20227 citationsauthor #15
Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
202229 citationsauthor #13
2022-RA-703-ESGO Primary and interval debulking surgery in advanced ovarian cancer: real-world clinical outcomes of patients in 1st line setting, analysis from the french national ESME-unicancer database
20220 citationsauthor #16
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database
20228 citationsauthor #10
Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak
20222 citationsauthor #11
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer
20210 citationsauthor #15
Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program
202121 citationsauthor #22
102P Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases: Characteristics and validation of prognostic models in a large real-life database
20210 citationsauthor #16
Abstract PD10-08: Outcomes of germline BRCA carriers versus non-carriers in the french national metastatic breast cancer ESME cohort 2008-2016
20211 citationsauthor #10
Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program
20212 citationsauthor #16
231P Prognosis and efficacy of frontline treatment for HR+ HER2- metastatic breast cancer occurring in gBRCA1/2 carriers
20210 citationsauthor #13
Abstract PS7-46: Enrollment of older metastatic breast cancer patients in clinical trials
20210 citationsauthor #17
A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab
20213 citationsauthor #12
Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer
20213 citationsauthor #15
Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic
202150 citationsauthor #16
Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort
202120 citationsauthor #17
Unhealthy behaviors after breast cancer: Capitalizing on a teachable moment to promote lifestyle improvements
202130 citationsauthor #21
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
2021110 citationsauthor #18
Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database
202141 citationsauthor #17
Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients
202110 citationsauthor #14
Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database
20219 citationsauthor #21
Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008-2016.
20207 citationsauthor #20
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study
20207 citationsauthor #6
Abstract P2-13-03: Lifestyle changes after breast cancer: A prospective study among 8580 women
20200 citationsauthor #16
Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.
202023 citationsauthor #2
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
2020161 citationsauthor #19
Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database
20204 citationsauthor #21
930P Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head & neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapy
20201 citationsauthor #10
Clinical outcome of patients experiencing central nervous system progression on first-line pertuzumab and trastuzumab for HER2-positive metastatic breast cancer in a real-life cohort.
20200 citationsauthor #13
Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size
20202 citationsauthor #3
Persistent taxane‐induced neuropathy in elderly patients treated for localized breast cancer
202017 citationsauthor #7
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
2020135 citationsauthor #14
Abstract P1-19-19: Treatments and outcome in older versus younger women with HER2-positive metastatic breast cancer in the multicenter national observational ESME database
20200 citationsauthor #20
306P Real-life management and prognosis of young women (≤ 40 yo) with de novo metastatic breast cancer in the multicenter national observational ESME program
20200 citationsauthor #16
Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A 3‐arm randomized trial
202053 citationsauthor #13
Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis.
202031 citationsauthor #22
Impact of body mass index on overall survival in patients with metastatic breast cancer
202037 citationsauthor #12
[COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence, in collaboration with the College Nationale des Gynecologues et Obstetriciens Francais (CNGOF), the Societe d'Imagerie de la FEMme (SIFEM),
20201 citationsauthor #28
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort
202043 citationsauthor #18
280MO Progression free survival with endocrine therapy, before or after chemotherapy, in patients with hormone receptor-positive/HER2-negative metastatic breast cancer in a large multicenter national observational study
20200 citationsauthor #15
PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer
20207 citationsauthor #9
Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol
20207 citationsauthor #4
Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study
20205 citationsauthor #18
Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)
20201 citationsauthor #11
Abstract P5-06-18: Prediction of PFS and OS under third and fourth line chemotherapy among metastatic triple-negative breast cancer patients in the national multicenter ESME metastatic breast cancer cohort
20200 citationsauthor #16
Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
201910 citationsauthor #8
Prognosis value of a genetic score based on germline genetic variants in a prospective cohort of early triple-negative breast cancer patients.
20190 citationsauthor #13
Baseline quality of life (QoL) and chemotherapy related toxicities (CRT) in localized breast cancer (BC) patients (pts): The French multicentric prospective CANTO cohort study
20190 citationsauthor #13
Abstract P5-17-04: Metastatic inflammatory breast cancer: Clinical features and outcomes in the national, multicentric, real-life ESME cohort
20190 citationsauthor #19
EP967 Natural history of patients with BRCA-mutated high grade epithelial ovarian cancer (HGEOC) before the era of PARP inhibitors maintenance in 1st line treatment
20192 citationsauthor #20
Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study
201960 citationsauthor #9
A new agent in the family of antibody-drug conjugates.
20190 citationsauthor #2
Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program
201932 citationsauthor #18
Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors: A prospective patient-reported outcomes (PRO) analysis.
20192 citationsauthor #10
Prognostic impact of body mass index (BMI) on overall survival in patients with metastatic breast cancer
20192 citationsauthor #12
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
2019190 citationsauthor #18
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
2019193 citationsauthor #15
Agranulocytosis Induced by Tamoxifen in a Breast Cancer Patient
20197 citationsauthor #3
Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.
201946 citationsauthor #19
Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis
201855 citationsauthor #22
Efficacy of anthracycline/taxane‐based neo‐adjuvant chemotherapy on triple‐negative breast cancer in BRCA1/BRCA2 mutation carriers
201827 citationsauthor #14
Abstract P6-08-10: Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life "ESME" cohort
20181 citationsauthor #20
Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program.
20183 citationsauthor #11
Abstract P6-14-02: Real-life activity of eribulin among metastatic breast cancer patients in the multicenter national observational ESME program
20181 citationsauthor #18
Abstract P6-14-06: Oral etoposide (VP-16) in heavily pre-treated metastatic breast cancer: A multicenter national observational study
20180 citationsauthor #19
Outcomes of 9800 metastatic luminal HER2-negative breast cancer patients in the French national real-life UNICANCER ESME-breast cohort
20180 citationsauthor #13
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
2018258 citationsauthor #18
Can we establish a hierarchy among trastuzumab biosimilar candidates?
20188 citationsauthor #2
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME MBC COHORT
20181 citationsauthor #19
Abstract P1-07-07: Overtime distribution and predictors of local recurrences (LRs) in patients with hormone receptor positive (HR+) and node positive (N+) breast cancers (BCs): 10 -year follow-up analysis of UNICANCER-PACS 01 and PACS04 trials
20180 citationsauthor #15
Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens
20187 citationsauthor #17
Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer
20186 citationsauthor #16
Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG).
201832 citationsauthor #14
266PUse of everolimus in advanced hormone receptor positive metastatic breast cancer in a multicenter national observational study
20170 citationsauthor #11
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort
20174 citationsauthor #10
Evolution of overall survival according to year of diagnosis (2008-2014) and subtypes, among 16703 metastatic breast cancer (MBC) patients included in the real-life "ESME" cohort.
20174 citationsauthor #17
Use of everolimus in advanced hormone receptor–positive metastatic breast cancer in a multicenter national observational study.
20171 citationsauthor #11

TIMELINE

1994 2 citations

1995 18 citations

1996 25 citations

1997 11 citations

1998 12 citations

1999 44 citations

2000 12 citations

2001 198 citations

2002 138 citations

2003 49 citations

2004 302 citations

2005 61 citations

2006 71 citations

2007 593 citations

2008 6 citations

2009 652 citations

2010 75 citations

2011 210 citations

2012 261 citations

2013 50 citations

2014 714 citations

2015 70 citations

2016 361 citations

2017 10 citations

2018 399 citations

2019 544 citations

2020 542 citations

2021 300 citations

2022 189 citations

2023 54 citations

T. Petit

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT